Definitive Contract 75F40122C00148
- Not listed
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $49,995,944 definitive cost-no-fee contract to Vanderbilt University Medical Center for Surveillance of Acutely Ill Adults with Respiratory Viruses, Including SARS-CoV-2. Vanderbilt University Medical Center will serve as the prime contractor and has subcontracted portions of the work to 26 other institutions, including The Cleveland Clinic Foundation, University of Utah, Beth Israel Deaconess...
- This contract was awarded by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to the Icahn School of Medicine at Mount Sinai, a private medical school in New York City. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant infections, and emerging infectious diseases, with a potential value of $22,709,915.00. It is a definitive, cost-no-fee contract with a completion date...
- This is a $13,460,835.60 delivery order awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to Vanderbilt University Medical Center. The contract is for an Adult Inpatient and Outpatient VE Case Control Study, which will evaluate the effectiveness of COVID-19 and influenza vaccines. This order falls under the larger Safety and Healthcare Epidemiology Prevention Research Development 2016 (SHEPheRD 2016) indefinite delivery/indefinite quantity...
- This is a $4,410,023.00 firm-fixed price contract awarded by the Centers for Disease Control and Prevention (CDC) to Nova Southeastern University, Inc., a private, non-profit research university, to conduct research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The contract does not have a set-aside designation. Under this contract, Nova Southeastern University will serve as the prime contractor, with Vanderbilt University Medical Center and the University of Miami acting as...
- This federal contract was awarded by the Veterans Integrated Service Network 2 (VISN 2), a division of the U.S. Department of Veterans Affairs, to New York University (NYU) School of Medicine. The $77,639.99 firm fixed-price delivery order is for research services, with a completion date of July 7, 2023. The contract is not a set-aside. This award falls under a larger Indefinite Delivery Contract held by NYU School of Medicine with the Centers for Disease Control and Prevention (CDC) Safe...
- This is a $11,665,406.62 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to The Washington University, a private university in St. Louis, Missouri. The contract supports "B Cell Epitope Discovery and Mechanisms of Antibody Protection" research, with no set-aside designation. The contract includes several subcontractors: Vanderbilt University Medical Center is developing panels of human monoclonal antibodies against flaviviruses and...
- This is a $1,050,310 firm fixed-price definitive contract awarded by the Food and Drug Administration (FDA) to the Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The contract, which has no set-aside designation, is for a project titled "CDER NEURODEVELOPMENTAL AND MENTAL HEALTH OUTCOMES IN PRETERM INFANTS: EFFECTS OF EXP" with a period of performance ending on March 7, 2025. The contract was awarded under a Broad Agency...
- The Food and Drug Administration awarded a $3.96M cost-plus-no-fee definitive contract to The Leland Stanford Junior University to conduct research on the pathology and pathogenesis of coronavirus infections in animal models. Originally awarded on September 30, 2020, the contract has been modified to extend performance through March 30, 2026. The work was solicited through the FDA's Broad Agency Announcement for regulatory science and innovation, which sought advanced research and development...
- The U.S. Department of Veterans Affairs (VA) has awarded a $30,774.54 firm fixed price delivery order contract to New York University (NYU) School of Medicine for research services. The contract has a period of performance through December 31, 2024. NYU School of Medicine is a leading academic medical center and research institution that conducts extensive biomedical and clinical research. The contract is not set aside for any specific business type. NYU School of Medicine has a significant...
- This federal contract award is for tuition and fees to support medical education programs at New York Medical College (NYMC), a private non-profit university located in Valhalla, New York. The $102,680.00 firm-fixed price delivery order was awarded on May 10, 2024 by the Department of the Navy Bureau of Medicine and Surgery, a defense agency, with a performance period through December 31, 2024. NYMC, which is a subsidiary of the larger Touro University system, has a long-standing relationship...
This is a $2,573,555.62 firm fixed price contract awarded by the Food and Drug Administration (FDA) to New York Medical College (NYMC), a private non-profit university, to characterize the clinical presentation of COVID-19 vaccine-associated myocarditis (C-VAM) and contrast it with cardiac complications of SARS-CoV-2 infection. The contract will inform best practices for surveillance and monitoring of C-VAM, including in asymptomatic individuals. This contract is not associated with a set-aside program. NYMC is a subsidiary of Touro University, a private non-profit educational institution that has a history of federal contract and grant awards, particularly with the U.S. Department of the Navy's Bureau of Medicine and Surgery to provide medical education and training services.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Other Administrative Action | $576.5k | 9/22/25 | |
| P00001 | Other Administrative Action | $0 | 8/12/25 | |
| Not listed | Not listed | $2.0m | 9/26/22 |